Table 4.

HRs of the copresence of HDL cholesterol <1.0 mmol/L and nonuse of metformin during follow-up versus all other groups for site-specific cancers and fatal and nonfatal cancers

	Number of cancers	HR (95% CI)*	P
Cancer subtypes†
1) Lip, oral cavity, and pharynx	6
2) Respiratory and intrathoracic organs	16
3) Genitourinary organs	16
4) Lymphatic and hematopoietic tissue	19
5) Bone, connective tissue, skin, and breast	7
6) Other and unspecified sites	19
Cancer at sites other than digestive organs and peritoneum (1–6 combined)	77	4.06 (2.39–6.89)	<0.0001
7) Digestive organs and peritoneum	65	2.31 (1.17–4.54)	0.0153
Fatal and nonfatal cancers‡
Fatal cancer	56	3.42 (1.80–6.49)	0.0002
Nonfatal cancer	119	2.70 (1.67–4.37)	<0.0001

*Univariable Cox models with stratification on deciles of the propensity score of use of metformin during follow-up were used to obtain the HRs.

†Classification was based on the ICD-9 (there are overlaps among site-specific cancers).

‡46 nonfatal cancer events developed before fatal cancer.